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ABSTRACT 
The role of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in neurosurgical practice 
is a secondary one, however they are still constantly involved in perioperative 
management of pain or in nonoperative management of acute radiculopathy. Beside 
the well-known adverse reactions (ADRs), the neurosurgeon practitioner should also 
take in account the drug hypersensitivity reactions (DHRs) of NSAIDs and be able to 
deal with it. The aim of this paper was to review the diagnostic and management 
steps for NSAIDs-induced Hypersensitivity Reactions. The actual stratification of 
NSAIDs-induced Hypersensitivity Reactions is based on understanding of the 
heterogeneity of immunological/non-immunological mechanisms of reactions and 
complexity of clinical manifestations. Practically, this stratification allows the 
physician to assess suspicion of DHR, based on anamnesis and clinical analysis, and 
to consider further practical steps to manage and eventually confirm the diagnosis. 
Drug allergies are considered only the DHRs for which a definite immunological 
mechanism (either drug-specific antibody or T cell) is demonstrated. In conclusion, 
clinical analysis and anamnesis of patient with NSAIDs-induced Hypersensitivity 
Reactions can be realized by any physician and could be enough to diagnose, but it is 
not sufficient to confirm the diagnosis. In vitro tests and oral provocation challenges 
may be necessary to be undertaken by an allergy specialist. 
 
 
INTRODUCTION 
Post-operative pain management in neurosurgery is very complex 
because the administration of some drugs might interfere with 
postoperative outcomes or with the neurological evaluation22. Although 
the use of nonsteroidal anti-inflammatory drugs (NSAIDs) in 
neurosurgery has been restricted due to their platelet dysfunction and 
risk of intracerebral bleeding, the postoperative pain is a nociceptive 
type pain which responds well to NSAIDs17. Furthermore, NSAIDs are 
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effective to reduce morphine requirements by 25%–
50% in a broad spectrum of postoperative 
(consequently decreasing adverse effects secondary 
to opioids administration) and for rescue analgesia 
in post-craniotomy pain management (may have 
even greater benefit when administered 
preemptively)8,22. The use of NSAIDs has been proved 
to be efficient also for the pain management after 
spine surgery19,21. Besides perioperatory 
involvement, NSAIDs are often prescribed (for short 
term) in addition to muscle relaxants and oral 
corticosteroids for nonoperative management of 
acute cervical radiculopathy4,10. 
A recent study from the UK, conducted by 
Marinho et al., in 2016, reported the use of mainly 
opioids (82%) by anesthesists, followed by 
paracetamol (56%) and NSAIDs (28%). Diclofenac was 
the most commonly used NSAID for perioperative 
pain, followed by parecoxib and ibuprofen15. In a 
survey study of 31 neurosurgical units in Great 
Britain, 42% of these reported prescribing NSAIDs, 
with 19 % prescribing NSAIDs on a regular basis for 
post-craniotomy analgesia13.  
Drug Hypersensitivity Reactions (DHRs) after 
NSAIDs administration are less taken into account by 
practitioners, because gastrointestinal bleeding, 
platelet dysfunction, increased bleeding times and 
cardiovascular risk are the most known and severe 
adverse drug reactions induced by NSAIDs6. 
Depending on the method of assessment, the 
analyzed population and type of reaction, the 
general prevalence of NSAIDs hypersensitivity 
ranges from 0.6 to 6% and according to the Online 
Latin American Survey on Anaphylaxis (OLASA), 
NSAIDs were the culprit agents in 73% of the drug-
induced anaphylaxis18.   
NSAIDs are frequently involved in DHRs because 
they are frequently prescribed at all ages. Every 
practitioner should be aware that any drug can 
induce a DHR and the NSAIDs (especially Ibuprofen) 
beside some antibiotics are more likely to be the 
culprit for immediate reactions such urticaria and 
anaphylaxis6. We propose a model of clinical 
approach for the neurosurgical patient with 
suspected NSAID hypersensitivity reaction. 
 
I. NSAIDS-INDUCED HYPERSENSITIVITY REACTIONS - 
DIAGNOSTIC STEPS 
According to WHO (World Health Organization), 
Adverse Drug Reactions induced by drugs are 
classified as: 
• A-type reactions: predictable and dose 
dependent, with a frequency of approximately 
75%; 
• B-type reactions or DHR: unpredictable and 
dose-independent, with a frequency of 
approximately 25%; based on their mechanisms 
these are classified as: 
o immunologically mediated (allergic reactions): 
due to a specific IgE or due to a T cell response 
o non-immunologically mediated (non-allergic 
reactions or cross-reactive): due to an 
increased release of cystenyl leukotrienes by 
inflammatory cells, secondary to the inhibition 
of COX-1 enzyme16; these are caused by 
changes of pharmacological pathways (e.g. 
inhibition of cyclooxygenase)14. 
 
In the general medical practice, when a drug allergic 
reaction is suspected, DHR is the used term, 
according to international consensus on drug 
allergy5. Drug allergies are considered only the DHRs 
for which a definite immunological mechanism 
(either drug-specific antibody or T cell) is 
demonstrated. 
Cross hypersensitivity represents the majority of 
DHRs induced by NSAIDs compared to specific 
immunological mediated-reactions (76 vs. 24%)14. 
Based on the time-lapse between the last drug 
administration and the onset of the reaction, the 
DHRs of NSAIDs are classified as5:  
• immediate reactions (usually immediate to 
several hours after the drug exposure): 
o IgE-mediated (immunological): 
▪ single-NSAID-induced urticarial / 
angioedema / anaphylaxis (SNIUAA) 
manifested as urticaria, angioedema 
and/or anaphylaxis induced by a single 
NSAID or by several NSAIDs belonging to 
the same chemical group in subjects that 
tolerate other chemically nonrelated 
NSAIDs and usually do not have a history 
of chronic urticaria or asthma → labeled 
as; 
o Non IgE-mediated (non-immunological or 
cross-reactive): 
▪ NSAIDs-exacerbated respiratory disease 
(NERD) manifested as bronchial 
obstruction, dyspnea, and nasal 
congestion/rhinorrhea induced by aspirin 
or other NSAIDs in patients with an 
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underlying chronic airway respiratory 
disease (asthma/rhinosinusitis/nasal 
polyps);  
▪ NSAIDs-exacerbated cutaneous disease 
(NECD) manifested as wheals and/or 
angioedema – induced by aspirin or other 
NSAIDs in patients with a history of chronic 
spontaneous urticaria; 
▪ NSAIDs-induced urticaria/angioedema 
(NIUA) manifested as wheals and/or 
angioedema – induced by aspirin or other 
NSAIDs (at least two NSAIDs with different 
chemical structure - not belonging to the 
same chemical group) in healthy subjects 
(without history of chronic spontaneous 
urticaria); 
• non-immediate reactions (usually more than 24 
h after exposure): 
o Single-NSAID-induced delayed 
hypersensitivity reactions (SNIDR) are T cell 
– mediated, manifested as cutaneous 
symptoms (exanthema), fixed drug eruption, 
Drug Reaction with Eosinophilia and Systemic 
Symptoms, acute generalized 
exanthematous pustulosis, Stevens-Johnson 
Syndrome/toxic epidermal necrolysis, severe 
organ-specific or systemic symptom – 
induced by a single NSAID. 
 
Immediate to several hours after the drug exposure, 
as a chronological stratification, has limitations:  
- the exact onset of initial symptoms might be 
hard to pinpoint;  
- the route of administration can influence 
the time interval in which the reaction 
occurs. 
- cofactors such as co-medications, food 
intake, alcohol and exercise, can speed up or 
slow down the onset or progression of a 
reaction2.  
 
 NSAIDs-induced hypersensitivity 
NSAIDs-Exacerbated 
Respiratory Disease 
(NERD) 
NSAIDs-
Exacerbated 
Cutaneous 
Disease (NECD) 
NSAIDs-
Induced 
Urticaria/ 
Angioedema 
(NIUA) 
Single-NSAID-
Induced Urticaria/ 
Angioedema or 
Anaphylaxis 
(SNIUAA) 
Single-NSAID-Induced Delayed 
Hypersensitivity Reactions  
(SNIDR) 
Clinical manifestations? 
 respiratory symptoms 
(bronchial obstruction, 
cough, wheezing dyspnea, 
and nasal 
congestion/rhinorrhea) 
 
wheals and/or angioedema 
 
urticaria, angioedema 
and/or anaphylaxis 
very diverse symptoms – from  
cutaneous symptoms (with 
different degree of severity) to 
severe organ-specific or systemic 
symptoms 
Onset time of the reaction? 
 1-2 hours after drug intake, up to 24 hours (when reaction occurs within minutes or 
during the 1st hour there is highly susceptible for SNIUAA or NERD/NECD) 
more than 24 hours after drug 
intake 
History/relapse of symptoms? 
 history of similar 
symptoms caused by other 
strong COX-1 inhibitor 
and/or history of good 
tolerance of selective COX-
2 
history of reaction to more than 
one chemically unrelated COX-1 
inhibitor 
 
 
history of cutaneous 
(urticaria and/or 
angioedema) and/or 
anaphylactic 
reactions to a single 
NSAID 
usually no typical history 
Underlying chronic diseases? 
 asthma and/or 
rhinosinusitis with nasal 
polyps 
episodes of 
spontaneous 
chronic urticaria / 
angioedema, 
unrelated to 
NSAIDs 
typical no underlying diseases 
 
Table 1. Diagnosis steps for NSAIDs-induced hypersensitivity 
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After the physician has gone through previous 
anamnesis and corroborates the obtained clinical 
data with DHRs classification represented in Table 1, 
there is a high probability to clinically diagnose a DHR 
as follows: 
• the typical form of SNIDR can be clinically 
diagnosed (heterogenic reactions, mainly 
cutaneous symptoms, 24 h or more after last 
drug administration), but in clinical practice, in 
time-lapse between the intake of culprit drug and 
onset of delayed reactions other drugs are 
administrated, which can make the diagnosis 
assessment difficult; 
• NERD can be suspected when a patient with 
asthma and/or rhinosinusitis with nasal polyps 
accuses respiratory symptoms (cough, wheezing, 
dyspnea, nasal congestion, nasal discharge). The 
diagnosis of NERD is confirmed if he reports a 
history of similar symptoms after other strong 
COX-1 inhibitors and/or history of good tolerance 
of selective COX-2; 
• in the case of acute cutaneous symptoms 
(urticaria/angioedema) and/or anaphylactic 
symptoms after intake of NSAIDs, we have to 
distinguish between three subtypes of 
hypersensitivity: NECD, NIUA or SNIUAA. The 
detailed history of previous reactions establishes 
whether the patient is sensitized to a single drug 
or is the case of a cross-reactive type of NSAIDs 
hypersensitivity: 
o allergic type I reaction (SNIUAA) is based on a 
history of cutaneous (urticaria and/or 
angioedema) and/or anaphylactic reactions to 
a single NSAID. 
o nonallergic type reaction (cross-reactive) is 
suspected in a patient with history of more 
than one chemically unrelated COX-1 
inhibitor. The diagnosis of NECD is based on 
history of episodes of spontaneous chronic 
urticaria/angioedema to several chemically 
unrelated NSAIDs. The diagnosis of NIUA is 
based on history of hypersensitivity 
cutaneous reactions to several chemically 
unrelated NSAIDs concomitant and a negative 
history of spontaneous urticaria/angioedema. 
 
The clinical reality may not always look like in the 
above description – 10% of patients with NECD have 
respiratory symptoms (bronchoconstriction) that 
resembles the NERD23. Moreover than this, 
concomitant rhino-conjunctivitis in patients with 
NSAID-induced cutaneous reactions are reported3. 
 
II. NSAIDS-INDUCED HYPERSENSITIVITY REACTIONS - 
MANAGEMENT 
The main indication in case of an already diagnosed 
NSAID DHR is the avoidance of drugs from the same 
family. However, the neurosurgeon has the 
possibility of an alternative NSAID related on type of 
DHR: 
• in the case of SNIUAA, when the specific NSAID 
has been identified, it can be replaced by another 
NSAID with similar anti-inflammatory potency but 
an unrelated chemical structure; 
• in the case of NERD/NECD, preferential COX-2 
inhibitors (around 91 to 99% of patients with 
hypersensitivity NSAIDs tolerate meloxicam - 
doses higher than 15 mg daily should be avoided) 
and highly selective COX-2 inhibitors (celecoxib 
with a rate of only 4% positive reactions and 
etoricoxib with a rate of reactions ranging from 
2,9% to 4%) are generally well tolerated9,11,12; 
leukotriene-modifying drugs may bring benefits 
in correlation with standard chronic urticaria 
management1; 
• NIUA – avoidance of NSAIDs (desensitization 
done by allergolog). 
 
In case of patients who have taken multiple drugs (in 
addition to an NSAID), the administration of 
alternative drugs has to be suspended firstly; drugs 
continuously taken for months are not suspected 
(exception is angiotensin-converting-enzyme which 
can develop angioedema after months or even years 
of intake).  
 Particularly when a patient, with known DHR to a 
COX-1 inhibitor, needs urgently analgesic 
medication, the opioids should be recommended 
due to the differences in structure. Also the selective 
COX-2 might be an alternative, but a benefit – risk 
analysis is imperative. 
 
III. NSAIDS-INDUCED HYPERSENSITIVITY REACTIONS WITH 
POTENTIAL OF SEVERE PROGRESSION 
In the case of a suspected DHR, a severe progression 
should always be taken into account. According to 
Scherer K et. al and to the more recently task force 
report of European Academy of Allergy and Clinical 
Immunology, the severe progression could be 
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indicated by the presence of some clinical signs 
[20,7] (Table 2). 
 
Immediate reaction 
(anaphylaxis) 
Non-Immediate reaction 
(delayed reaction) 
• Severe urticaria 
• Rapid onset of 
extensive pruritus 
(especially scalp and 
palmo-plantar) 
• Angioedema of the 
oral mucosa 
(especially pharynx 
and larynx) 
• Hypotension  
• Conjunctivitis and 
rhinitis with flush on 
face and neck  
• Dyspnea with 
bronchospasm 
(particularly in 
asthmatics) 
Cutaneous symptoms: 
• Hemorrhagic necrotizing 
lesions 
• Centrofacial edema 
(diffuse erythematous 
swelling) 
• Purpura  
• Involvement of large 
body surfaces or 
erythroderma 
• Painful skin 
• Atypical target lesions 
• Nikolsky sign positive 
• Erosive stomatitis 
• Mucositis (involving 
more than one mucosal 
area) 
Symptoms suggesting 
internal organ involvement: 
• Unexplained rapid onset 
of high fever (> 39 °C)  
• Arthritis and arthralgias  
• Disseminated 
lymphadenopathy 
 
Table 2. Clinical signs for a potential severe progression of 
NSAIDs-induced hypersensitivity reactions. 
 
IV. CRITERIA TO REFER A PATIENT WITH DHS TO ALLERGIST 
 
First steps that include a clinical analysis and 
anamnesis of patient can be realized by a non-
specialist and could be enough to diagnose in some 
cases, but frequently NSAID hypersensitivity, is not 
sufficient to confirm the diagnosis (Fig. 1). In vitro 
tests and oral provocation challenges may be 
necessary to be undertaken by an allergy specialist. 
 
 
 
 
Figure 1. Criteria to refer a patient with DHS to allergist 
 
Up to 1/3 of patients with chronic spontaneous 
urticarial report exacerbations of cutaneous 
symptoms upon ingestion of NSAIDs. The level of 
sensitivity could temporary variate in relation to 
coexisting chronic spontaneous urticaria and 
consequently, sensitivity may decrease and even 
disappear – therefore reassessing the tolerance to 
NSAIDs is appropriate14. 
 
CONCLUSIONS 
The neurosurgical practice implies often moderate-
to-severe postoperative pain in a multitude of 
procedures such as craniotomies for aneurysm 
clipping, craniotomies for tumor resections and 
epilepsy surgery, neuroradiological procedures and 
penetrating traumatic brain injury. Post-operative 
pain management is very complex due to 
interference of drugs with postoperative outcomes 
or with the neurological evaluation22. Nociceptive 
type pain responds well to NSAIDs, even their use in 
neurosurgery has been restricted due to the platelet 
dysfunction and risk of intracerebral bleeding17. 
Diagnosing DHRs is a complex issue. Clinical analysis 
and diagnostic of a DHR can be realized by any 
physician, but the confirmation of the diagnosis 
needs in vitro tests and oral provocation challenges 
which should be undertaken by an allergy specialist. 
If the NSAID-induced hypersensitivity is confirmed, 
• suspected DHR to NSAIDs and increased probability of the use of this group of drugs 
in the future
• history of severe DHR (anaphylaxis or severe non-immediate cutaneous reaction).
When is mandatory?
• suspected, but not severe DHR to NSAIDs; no estimated NSAIDs use in the future.
When is recommended?
• 4–6 weeks after the complete resolution of all clinical symptoms (after 6–12 months, 
the results may be false negative7).
When is the appropriate time-lapse for allergological investigations?
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recommendations based on the current 
classification for drug avoidance, use of alternative 
NSAIDs, and other management modalities, 
including aspirin desensitization, can be 
implemented. 
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